The company's US subsidiary, Wockhardt USA Inc would launch Divalproex Sodium in the US market after the patent for the drug expires on January 29, 2008.
Divalproex Sodium is the generic version of Abbott's Depakote DR tablets and the market for the product in the US is $802 million, Wockhardt informed the Bombay Stock Exchange.
The drug is Wockhardt's first product incorporating novel drug delivery system to be cleared for sale in the US.
"Our US business is on the fast growth track, this is our third USFDA approval in three weeks and the fifth this year. We have 20 more products awaiting USFDA approval," Habil Khorakiwala, chairman, Wockhardt said.
Divalproex Sodium would be manufactured at the company's API (active pharmaceutical ingredient) facility at Ankleshwar while the tablets would be manufactured at the formulation plant in Aurangabad, both certified by USFDA.
The company currently markets 13 products in the US. The shares of the company were trading at Rs 336.80, up 3.73 per cent at the BSE.
© 2025